298 related articles for article (PubMed ID: 15922013)
21. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor.
Deakin S; Leviev I; Brulhart-Meynet MC; James RW
Biochem J; 2003 Jun; 372(Pt 2):643-9. PubMed ID: 12639220
[TBL] [Abstract][Full Text] [Related]
22. Distribution of paraoxonase PON1 gene polymorphisms in Mexican populations. Its role in the lipid profile.
Gamboa R; Zamora J; Rodríguez-Pérez JM; Fragoso JM; Cardoso G; Posadas-Romero C; Vargas-Alarcón G
Exp Mol Pathol; 2006 Feb; 80(1):85-90. PubMed ID: 15993880
[TBL] [Abstract][Full Text] [Related]
23. Discordance in human paraoxonase-1 gene between phenotypes and genotypes in chronic kidney disease.
Paragh G; Seres I; Harangi M; Pocsai Z; Asztalos L; Locsey L; Szeles G; Kardos L; Varga E; Karpati I; Adany R
Nephron Clin Pract; 2009; 113(1):c46-53. PubMed ID: 19602899
[TBL] [Abstract][Full Text] [Related]
24. Maternal exposure to floricultural work during pregnancy, PON1 Q192R polymorphisms and the risk of low birth weight.
Moreno-Banda G; Blanco-Muñoz J; Lacasaña M; Rothenberg SJ; Aguilar-Garduño C; Gamboa R; Pérez-Méndez O
Sci Total Environ; 2009 Oct; 407(21):5478-85. PubMed ID: 19646734
[TBL] [Abstract][Full Text] [Related]
25. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity.
Costa LG; Cole TB; Vitalone A; Furlong CE
Clin Chim Acta; 2005 Feb; 352(1-2):37-47. PubMed ID: 15653099
[TBL] [Abstract][Full Text] [Related]
26. Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS.
Wills AM; Landers JE; Zhang H; Richter RJ; Caraganis AJ; Cudkowicz ME; Furlong CE; Brown RH
Neurology; 2008 Mar; 70(12):929-34. PubMed ID: 18347314
[TBL] [Abstract][Full Text] [Related]
27. Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans.
Lacinski M; Skorupski W; Cieslinski A; Sokolowska J; Trzeciak WH; Jakubowski H
Cell Mol Biol (Noisy-le-grand); 2004 Dec; 50(8):885-93. PubMed ID: 15704252
[TBL] [Abstract][Full Text] [Related]
28. Genetically determined susceptibility to organophosphorus insecticides and nerve agents: developing a mouse model for the human PON1 polymorphism.
Furlong CE; Li WF; Costa LG; Richter RJ; Shih DM; Lusis AJ
Neurotoxicology; 1998; 19(4-5):645-50. PubMed ID: 9745924
[TBL] [Abstract][Full Text] [Related]
29. PON1 activity and genotype in patients with arterial ischemic stroke and in healthy individuals.
Schiavon R; Turazzini M; De Fanti E; Battaglia P; Targa L; Del Colle R; Fasolin A; Silvestri M; Biasioli S; Guidi G
Acta Neurol Scand; 2007 Jul; 116(1):26-30. PubMed ID: 17587252
[TBL] [Abstract][Full Text] [Related]
30. Arylesterase and paraoxonase activity of paraoxonase (PON1) affected by ischemia in the plasma of patients with arterial occlusion of the lower limbs.
Kasprzak M; Iskra M; Majewski W; Wielkoszyński T
Clin Biochem; 2009 Jan; 42(1-2):50-6. PubMed ID: 18976644
[TBL] [Abstract][Full Text] [Related]
31. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1.
Deakin SP; James RW
Clin Sci (Lond); 2004 Nov; 107(5):435-47. PubMed ID: 15265000
[TBL] [Abstract][Full Text] [Related]
32. Relation of PON1 and CYP1A1 genetic polymorphisms to clinical findings in a cross-sectional study of a Greek rural population professionally exposed to pesticides.
Tsatsakis AM; Zafiropoulos A; Tzatzarakis MN; Tzanakakis GN; Kafatos A
Toxicol Lett; 2009 Apr; 186(1):66-72. PubMed ID: 19022366
[TBL] [Abstract][Full Text] [Related]
33. Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease.
Kerkeni M; Addad F; Chauffert M; Chuniaud L; Miled A; Trivin F; Maaroufi K
Clin Biochem; 2006 Aug; 39(8):821-5. PubMed ID: 16875684
[TBL] [Abstract][Full Text] [Related]
34. Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting cad risk in North-West Indian Punjabis.
Gupta N; Singh S; Maturu VN; Sharma YP; Gill KD
PLoS One; 2011; 6(5):e17805. PubMed ID: 21629682
[TBL] [Abstract][Full Text] [Related]
35. Variability of the paraoxonase gene (PON1) in Euro- and Afro-Brazilians.
Allebrandt KV; Souza RL; Chautard-Freire-Maia EA
Toxicol Appl Pharmacol; 2002 May; 180(3):151-6. PubMed ID: 12009854
[TBL] [Abstract][Full Text] [Related]
36. PON1 status is influenced by oxidative stress and inflammation in coronary heart disease patients.
Kotur-Stevuljevic J; Spasic S; Jelic-Ivanovic Z; Spasojevic-Kalimanovska V; Stefanovic A; Vujovic A; Memon L; Kalimanovska-Ostric D
Clin Biochem; 2008 Sep; 41(13):1067-73. PubMed ID: 18634772
[TBL] [Abstract][Full Text] [Related]
37. PON1 gene polymorphisms and plasma PON1 activities in Takayasu's arteritis disease.
Huesca-Gómez C; Soto ME; Castrejón-Téllez V; Pérez-Méndez O; Gamboa R
Immunol Lett; 2013 Apr; 152(1):77-82. PubMed ID: 23628180
[TBL] [Abstract][Full Text] [Related]
38. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.
Sumegová K; Blazícek P; Waczulíková I; Zitnanová I; Duracková Z
Acta Biochim Pol; 2006; 53(4):783-7. PubMed ID: 17106515
[TBL] [Abstract][Full Text] [Related]
39. Interaction between human serum esterases and environmental metal compounds.
Hernández AF; Gil F; Leno E; López O; Rodrigo L; Pla A
Neurotoxicology; 2009 Jul; 30(4):628-35. PubMed ID: 19393262
[TBL] [Abstract][Full Text] [Related]
40. 192R allele of paraoxanase 1 (PON1) gene as a new marker for susceptibility to bladder cancer.
Oztürk O; Kağnici OF; Oztürk T; Durak H; Tüzüner BM; Kisakesen HI; Cakalir C; Isbir T
Anticancer Res; 2009 Oct; 29(10):4041-6. PubMed ID: 19846948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
